78.63
-2.03 (-2.51%)
| Previous Close | 80.65 |
| Open | 80.86 |
| Volume | 126,417 |
| Avg. Volume (3M) | 571,647 |
| Market Cap | 2,968,106,240 |
| Price / Book | 5.27 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 4.64% |
| Current Ratio (MRQ) | 37.65 |
| Operating Cash Flow (TTM) | -101.70 M |
| Levered Free Cash Flow (TTM) | -66.74 M |
| Return on Assets (TTM) | -16.25% |
| Return on Equity (TTM) | -23.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Disc Medicine, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.65% |
| % Held by Institutions | 99.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2025 | 2,142,617 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 114.00 (Truist Securities, 44.99%) | Buy |
| Median | 111.50 (41.81%) | |
| Low | 109.00 (Wells Fargo, 38.63%) | Buy |
| Average | 111.50 (41.81%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 87.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 16 Dec 2025 | 109.00 (38.63%) | Buy | 91.47 |
| Truist Securities | 10 Nov 2025 | 114.00 (44.99%) | Buy | 83.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 |
| 12 Jan 2026 | Announcement | Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer |
| 07 Jan 2026 | Announcement | Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 06 Dec 2025 | Announcement | Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting |
| 06 Nov 2025 | Announcement | Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |